Future Targeted Therapy Approaches in NSCLC
Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.
Progress and Unmet Needs in NSCLC Treatment
Thoracic oncologists discuss the progress made and unmet needs that remain in the non–small cell lung cancer treatment space.
NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies
Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.
NSCLC: Dato-DXd Combination Therapy
Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.
Recent Data on Datopotamab Deruxtecan in NSCLC
An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.
Antibody-Drug Conjugate Safety Profiles in NSCLC
Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.
Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04
A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.
EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC
Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.
Clinical Trial Data on Sacituzumab Govitecan in NSCLC
Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.
Lung Cancer Treatment: Antibody-Drug Conjugates
Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.
NSCLC: Preclinical Studies on TROP2 Expression
A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.
The Role of TROP2 as a Biomarker in NSCLC
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.
NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates
Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.
The Role of Biomarkers in NSCLC Treatment
Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.
Overview of Non–Small Cell Lung Cancer
Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.
Coming Soon: Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs
Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.